Oncology / Talazoparib / Pitch
One of the lead concepts to represent the cutting edge MOA.
One of the lead concepts to represent the cutting edge MOA trapping activity inhibiting DNA damage repair.
gbrca+ is something that is past down on through DNA.
This is an invitation to oncologist to change history and the stop the cycle
gbrca+ is in her genes but now there is hope to chang outcome.
I concept/and developed a blog Site for Astra Zeneca oncology Pitch.
Talazoparib is an orally avaiable poly ADP ribose polymerase inhibitor developed by Pfizer for the treatment of advanced breast cancer with germline BRCA mutations. Talazoparib is similar to the first in class PARP inhibitor, olaparib.
-
Role Lead ACD in the development of pitch concepts, tactics, and branding
Up Next: